Welcome to our dedicated page for CNBX Pharms news (Ticker: CNBX), a resource for investors and traders seeking the latest updates and insights on CNBX Pharms stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CNBX Pharms's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CNBX Pharms's position in the market.
Cannabics Pharmaceuticals (OTCQB: CNBX) announced significant results from an in vivo study of its drug candidate, RCC-33, for colorectal cancer. The study demonstrated a 33% reduction in tumor volume compared to control mice, achieving statistical significance with a p-value of ≤ 0.016. This outcome is pivotal in advancing their research and development within cannabinoid-based therapies, positioning Cannabics as a leader in cancer treatment innovation. The company’s operations are based in Israel, under the license from the Ministry of Health.
Cannabics Pharmaceuticals (OTCQB: CNBX) announced promising results from its in-vivo study on RCC-33 for colorectal cancer, showing a 33% reduction in tumor volume versus control (p ≤ 0.016). The study involved inoculated mice receiving daily doses of RCC-33, with significant differences noted after 10 days. The oncology therapeutics market is projected to reach $250 billion by 2024, with a focus on addressing a $10 billion colorectal cancer segment. Cannabics plans to prepare a product dossier for FDA submission and requests for a pre-IND meeting.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced interim results from its ongoing in-vivo study of RCC-33, a drug candidate for colorectal cancer, revealing a 27% reduction in tumor volume after 12 days of treatment in nude mice compared to the control group. This significant result, with a p-value of 0.022, marks a promising development towards potential FDA approval. The study was initiated alongside the objective of improving survival rates for colorectal cancer patients, which currently stands at 67% for five-year survival with existing treatments.
Cannabics Pharmaceuticals (OTCQB: CNBX) announced the establishment of a dedicated division for its Antitumor Drug Candidate RCC-33, aimed at treating colorectal cancer. This move supports the company’s strategy to enhance clinical validation efforts, including in-vivo experiments and collaborations with medical centers. CEO Eyal Barad emphasized the significance of this initiative, while Medical Director Dr. Erez Scapa highlighted the potential positive impact of RCC-33 on colorectal cancer patients. Cannabics focuses on personalized cannabinoid therapies for cancer.
FAQ
What is the current stock price of CNBX Pharms (CNBX)?
What is the market cap of CNBX Pharms (CNBX)?
